Table 3.

Cholesterol content in subfractions of intermediate- and low-density lipoproteins at baseline and after lipid-lowering therapy

Lipoprotein subfractions	Simvastatin plus ezetimibe N = 50	Rosuvastatin monotherapy N = 51	P value
At baseline (D1)
IDL-A	16.0 (10.1–21.4)	12.5 (8.5–17.8)	0.06
IDL-B + C	40.1 (31.9–49.4)	35.2 (24.6–43.9)	0.02
LDL-1 + 2	50.4 (39.2–63.2)	52.5 (41.3–64.2)	0.38
LDL-3 + 4 + 5 + 6 + 7	3.6 (0.0–9.9)	2.8 (0.0–5.7)	0.09
After 30 days (D30)
IDL-A	8.8 (6.8–12.5)	7.5 (5.8–10.7)	0.15
IDL-B + C	22.0 (18.7–29.2)	20.6 (17.5–27.0)	0.21
LDL-1 + 2	25.0 (20.0–33.1)	24.8 (18.7–34.3)	0.96
LDL-3 + 4 + 5 + 6 + 7	1.8 (0.0–4.5)	2.0 (0.0–6.0)	0.75

Values are medians (IQRs) of cholesterol from subfractions of intermediate-density lipoproteins (IDL) and low-density lipoproteins (LDL). IDL-A is considered nonatherogenic, while IDL-B and IDL-C are atherogenic. LDL-1 and LDL-2 are large and buoyant (nonatherogenic), while LDL-3 to LDL-7 are considered atherogenic. Lipoprotein subfractions were adjusted by total serum cholesterol and are expressed in mg/dL. Data were compared by the Mann–Whitney U test